Related Articles
- The CLINCH examine is a Phase I/II examine ongoing in
China andAustralia with a dose escalation section adopted by a dose growth section. As ofNovember 22, 2024 , amongst 21 gastric most cancers sufferers in dose growth section with CLDN 18.2 expression of IHC 2+ ‰¥ 20% who had at least 1 tumor analysis, the general response fee (ORR) was 42.9%, and the illness management fee (DCR) was 95.2% (9 partial responses [PRs] together with 8 confirmed PRs; and 11 steady ailments [SDs]). - Amongst 10 gastric most cancers sufferers with CLDN 18.2 expression of IHC 2+ (1 full response [CR] and a couple of PRs, all PR/CR had been confirmed with CLDN 18.2 expression of IHC 2+ , and the DCR was 50.0%. The affected person with CR has demonstrated sturdy response and has been on the examine for over 14 months as of the closing date.
- ATN-022 demonstrated a manageable security profile and promising preliminary antitumor exercise in late stage gastric most cancers sufferers throughout numerous ranges of CLDN18.2 expression, supporting additional medical investigations of ATN-022 in gastric most cancers sufferers. The enrollment of gastric most cancers sufferers for dose optimization and sufferers with different stable tumors is ongoing in
China andAustralia .
Particulars of the Poster Presentation:
ATN-022 (often known as ATG-022, CLDN18.2 antibody-drug conjugate)
Security and Preliminary Efficacy of ATG-022 in Sufferers with Advanced/Metastatic Gastric Most cancers (CLINCH)
Summary Quantity: 456
Session: Poster Session A: Cancers of Esophagus and Abdomen and Different Gastrointestinal Cancers
Presenter: Jinfeng Ma Shanxi Most cancers Hospital
Date:
Time:
3:30 AM –
About ATN-022
ATN-022 is an antibody-drug conjugate (ADC) designed to focus on CLDN18.2, a member of the Claudin household of cell adhesion molecules. Underneath regular circumstances, Claudins are situated inside tight junctions between cells, forming a barrier to control cell permeability. Nevertheless, in most cancers, Claudins are aberrantly expressed on the cell floor on account of modifications in cell polarity. CLDN18.2 is often overexpressed in a variety of main malignant tumors, together with gastric, esophageal, cholangiocarcinoma, pancreatic and different cancers. The U.S. Meals and Drug Administration (FDA) has awarded Orphan Drug Designations to ATN-022, for gastric and pancreatic cancers.
Data from the continuing CLINCH examine of ATN-022 has proven promising medical efficacy in gastric most cancers sufferers with numerous ranges of CLDN18.2 expression. The efficacy already noticed throughout all ranges of CLDN18.2 expression in sufferers with gastric most cancers means that ATN-022 holds the promise as a aggressive remedy possibility.
About Antennova
Antennova, a
Ahead-Wanting Statements
The forward-looking statements made in this doc relate solely to the occasions or info as of the date on which the statements are made in this doc. Besides as required by regulation, we undertake no obligation to replace or revise publicly any forward-looking statements, whether or not in consequence of new info, future occasions or in any other case, after the date on which the statements are made or to mirror the incidence of unanticipated occasions. It’s best to learn this doc fully and with the understanding that our precise future outcomes or efficiency could also be materially totally different from what we anticipate. On this doc, statements of, or references to, our intentions or these of any of our Administrators or our Firm are made as of the date of this doc. Any of these intentions might alter in mild of future improvement.
For extra info, please contact:
Investor Relations
E mail: ir@antennova.com
[ad_2]
